Navigation Links
New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit
Date:4/13/2008

Cancer drug development guided by genomics

SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study identifying the genetic markers in patients more likely to respond to treatment with the experimental drug, brostallicin, at the 2008 American Association for Cancer Research (AACR) annual meeting. These findings will be used to guide future development of brostallicin by suggesting which patients are most likely to respond when treated with brostallicin, potentially making the drug's development more efficient. This method of drug development is known as the context of vulnerability approach. The study was co-directed by Jeffrey A. Kiefer, Ph.D., and Holly Yin, Ph.D. in the Translational Genomics Research Institute's Pharmaceutical Genomics Division located in Scottsdale, Arizona.

"This study is an example of using a pharmacogenomic screening approach to find insights that guide the selection of specific contexts of vulnerability for brostallicin. These results provide information on which genetic characteristics to look for in determining whether or not a patient might benefit from treatment with brostallicin. In SM and CTI's continued efforts to make cancer more treatable, results like these broaden our knowledge of brostallicin's context of vulnerability, and bring us closer to being able to offer the right drug to each patient," said Jeffrey Jacob, CEO of SM.

In the study, the NCI-60 cell line panel was profiled for brostallicin response and correlated with specific genomic information derived from the cell line panel. The NCI-60 is a group of 59 human cancer cell lines derived from tumor tissue -- brain, blood and bone marrow, breast, colon, kidney, lung, ovary, prostate, and skin. Scientists often use cell lines, also called models, in preclinical studies in a laboratory setting. The
'/>"/>

SOURCE Systems Medicine LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec
4. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
5. FASgen Announces a New Discovery in Obesity Research
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. Nobel Prize-Winning Discovery
8. FASgen Announces New Discovery for Treatment of Stroke
9. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
10. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
11. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 ... BVXV) today announced it received the statistical analysis of results ... (M-001), administered in the BVX-005 phase II trial which took ... strains which did not exist at the time of the ... strain that caused the epidemic in the United ...
(Date:8/3/2015)... 3, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... an exclusive licensing agreement to develop and commercialize multiple ... Limited, a holding company for premier antibody development and ... Under the terms of the agreement, Sorrento ... for the North American, European and Japanese market. Each ...
(Date:7/31/2015)... 31, 2015  Physicians and payers alone do ... market. Patients are better informed and getting increasingly ... therapies. This shift in power is reshaping the ... patient-focused marketing. As part of this ... it,s important to educate, communicate and engage patients ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive ... leaders from healthcare organizations with access to the tactics, techniques and practices required ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... too many clinicians still using unproven treatments , , ... and teens, individual and group cognitive behavioral therapy ... and other trauma symptoms, say U.S. researchers who ... subject. , However, despite the proven effectiveness of ...
... a criminal plea and pay $425 million to resolve ... by the Food and Drug,Administration (FDA), the Justice Department ... Cephalon employees and filed under,the qui tam provisions of ... in a scheme to market Gabitril, Actiq and Provigil ...
... Food Prices on the Rise New Tools to Help Make ... finance expert Suze Orman,is the latest celebrity to join the ... their health. With rising food costs, many,families are economizing on ... nutrition. At about 25 cents per 8 ounce glass, on ...
... In a letter to Dr. Mary S. ... ) board,s Governance Committee, the,CtW Investment Group questions ... Walgreens and challenges the arguments put forward by ... of Longs. Citing analysis prepared by expert anti-trust ...
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... LegalView recently informed mesothelioma blog readers of improper removal of asbestos ... risk for developing mesothelioma cancer. The city used an unapproved "wet ... asbestos dust once the water evaporates. , ... Denver, ...
Cached Medicine News:Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 3Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 4Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 5Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 2Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 4Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 5Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 6Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 3
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
... The proprietary Ambient Noise Reduction ... out anaverage of 75% of distracting ... acoustic canceling effect is different from ... out some portions of body sounds ...
... Afinion AS100 Analyzer ... on-the-spot testing, regardless of ... test was launched in ... CRP test in May ...
... Virion\Serions comprehensive line of ELISA Classic serology ... viral, and fungal pathogens with rapid, standardized ... IgA antibodies. All of the ELISA antigens ... in their own laboratories under the control ...
Medicine Products: